Puberty blocker trial will help reduce harm, says Cass report author (opens original article in a new tab)

A trial on puberty blockers for gender-questioning children, led by Dr. Hilary Cass, aims to assess their risks and benefits to reduce harm, despite legal challenges and ethical concerns.

• Dame Hilary Cass says a trial on puberty blockers for gender-questioning children is essential to reduce harm
• The Pathways trial will examine physical, social, and emotional impacts of puberty blockers on participants
• The trial has faced legal challenges from campaigners who argue it risks irreversible harm and lacks proper informed consent
• The NHS banned puberty blockers in 2024, but the trial aims to provide clinical evidence for future decisions